467 related articles for article (PubMed ID: 21233335)
1. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
3. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
4. The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model.
Pons B; Peg V; Vázquez-Sánchez MA; López-Vicente L; Argelaguet E; Coch L; Martínez A; Hernández-Losa J; Armengol G; Ramon Y Cajal S
Int J Oncol; 2011 Nov; 39(5):1337-45. PubMed ID: 21750861
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
6. Mnk mediates integrin α6β4-dependent eIF4E phosphorylation and translation of VEGF mRNA.
Korneeva NL; Soung YH; Kim HI; Giordano A; Rhoads RE; Gram H; Chung J
Mol Cancer Res; 2010 Dec; 8(12):1571-8. PubMed ID: 21047768
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Mitogen-activated Protein Kinase (MAPK)-interacting Kinase (MNK) Preferentially Affects Translation of mRNAs Containing Both a 5'-Terminal Cap and Hairpin.
Korneeva NL; Song A; Gram H; Edens MA; Rhoads RE
J Biol Chem; 2016 Feb; 291(7):3455-67. PubMed ID: 26668315
[TBL] [Abstract][Full Text] [Related]
8. Targeting of MNK/eIF4E overcomes chemoresistance in cervical cancer.
Zhu Y; Wang C; Li M; Yang X
J Pharm Pharmacol; 2021 Sep; 73(10):1418-1426. PubMed ID: 34254647
[TBL] [Abstract][Full Text] [Related]
9. A quassinoid 6alpha-tigloyloxychaparrinone inhibits hypoxia-inducible factor-1 pathway by inhibition of eukaryotic translation initiation factor 4E phosphorylation.
Jin X; Jin HR; Lee D; Lee JH; Kim SK; Lee JJ
Eur J Pharmacol; 2008 Sep; 592(1-3):41-7. PubMed ID: 18639543
[TBL] [Abstract][Full Text] [Related]
10. Regulation of eukaryotic initiation factor 4E (eIF4E) phosphorylation by mitogen-activated protein kinase occurs through modulation of Mnk1-eIF4G interaction.
Shveygert M; Kaiser C; Bradrick SS; Gromeier M
Mol Cell Biol; 2010 Nov; 30(21):5160-7. PubMed ID: 20823271
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Mnk-eIF4E pathway sensitizes the efficacy to chemotherapy in anaplastic thyroid cancer.
Hu K; Zhang J; Yu M; Xiong C
Future Oncol; 2017 Mar; 13(6):489-498. PubMed ID: 27785922
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
13. Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development.
Ueda T; Watanabe-Fukunaga R; Fukuyama H; Nagata S; Fukunaga R
Mol Cell Biol; 2004 Aug; 24(15):6539-49. PubMed ID: 15254222
[TBL] [Abstract][Full Text] [Related]
14. First MNKs degrading agents block phosphorylation of eIF4E, induce apoptosis, inhibit cell growth, migration and invasion in triple negative and Her2-overexpressing breast cancer cell lines.
Ramalingam S; Gediya L; Kwegyir-Afful AK; Ramamurthy VP; Purushottamachar P; Mbatia H; Njar VC
Oncotarget; 2014 Jan; 5(2):530-43. PubMed ID: 24504069
[TBL] [Abstract][Full Text] [Related]
15. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E.
Pyronnet S; Imataka H; Gingras AC; Fukunaga R; Hunter T; Sonenberg N
EMBO J; 1999 Jan; 18(1):270-9. PubMed ID: 9878069
[TBL] [Abstract][Full Text] [Related]
16. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
[TBL] [Abstract][Full Text] [Related]
18. Signal transduction pathways leading to increased eIF4E phosphorylation caused by oxidative stress.
Duncan RF; Peterson H; Sevanian A
Free Radic Biol Med; 2005 Mar; 38(5):631-43. PubMed ID: 15683719
[TBL] [Abstract][Full Text] [Related]
19. Rapamycin enhances eIF4E phosphorylation by activating MAP kinase-interacting kinase 2a (Mnk2a).
Stead RL; Proud CG
FEBS Lett; 2013 Aug; 587(16):2623-8. PubMed ID: 23831578
[TBL] [Abstract][Full Text] [Related]
20. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
